- $15.44m
- $15.05m
- $0.62m
Annual balance sheet for Mangoceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 0.023 | 0.683 | 0.739 | 0.059 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0.023 | 0.695 | 0.818 | 0.076 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0 | 0.292 | 0.215 | 0.062 |
| Net Intangible Assets | ||||
| Other Long Term Assets | ||||
| Total Assets | 0.023 | 1 | 1.05 | 15.4 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.039 | 0.261 | 0.211 | 1.43 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Minority Interest | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0.039 | 0.389 | 0.276 | 1.42 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -0.017 | 0.614 | 0.775 | 13.9 |
| Total Liabilities & Shareholders' Equity | 0.023 | 1 | 1.05 | 15.4 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |